Century Therapeutics Secures $126.4M in Private Placement, Extends Cash Runway to Q1 2029

summarizeSummary

Century Therapeutics reported Q1 2026 results, highlighting a $126.4 million private placement that significantly increased shares outstanding but extended its cash runway into the first quarter of 2029.

check_boxKey Events

• Q1 2026 Financial Results

  Reported a net loss of $21.6 million, a significant decline from a $76.6 million net income in Q1 2025, primarily due to the absence of one-time collaboration revenue from a terminated agreement.

• $126.4M Private Placement

  Completed in January 2026, raising net proceeds of $126.4 million through the issuance of 92 million common shares and warrants for approximately 71 million additional shares.

• Extended Cash Runway

  Cash and investments totaled $217 million as of March 31, 2026, following the private placement, which is projected to fund operations into Q1 2029.

• Significant Share Dilution

  The January 2026 private placement resulted in the issuance of 92 million common shares and warrants for approximately 71 million additional shares, more than doubling the shares outstanding from 87.5 million to 180.1 million.

auto_awesomeAnalysis

This quarterly report details the financial impact of a significant private placement completed in January 2026, which raised $126.4 million in net proceeds. While this transaction resulted in substantial dilution, increasing outstanding shares by over 100%, it critically extended the company's cash runway into the first quarter of 2029. This funding is essential for an early-stage biotech like Century Therapeutics, enabling continued development of its pipeline, including advancing CNTY-813 and CNTY-308 towards clinical trials. The company also reported a net loss for the quarter, primarily due to the absence of one-time collaboration revenue recognized in the prior year from a terminated agreement.